Cabazitaxel
- Generic Name
- Cabazitaxel
- Brand Names
- Jevtana, Cabazitaxel Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C45H57NO14
- CAS Number
- 183133-96-2
- Unique Ingredient Identifier
- 51F690397J
- Background
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrie...
- Indication
用于治疗转移性去势抵抗性前列腺癌患者。
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
Cabazitaxel and Radiation For Patients With Prostate Cancer
- First Posted Date
- 2012-07-26
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Brown University
- Target Recruit Count
- 5
- Registration Number
- NCT01650285
- Locations
- 🇺🇸
Miriam Hospital, Providence, Rhode Island, United States
A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes
- Conditions
- Interventions
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 31
- Registration Number
- NCT01620242
- Locations
- 🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷Centre Léon Berard, Lyon, France
🇫🇷Centre Antoine Lacassagne, Nice, France
A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)
- First Posted Date
- 2012-05-17
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 19
- Registration Number
- NCT01600339
- Locations
- 🇮🇱
Rambam MC, Haifa, Israel
🇮🇱Rabin Medical Center, Petah Tikva, Israel
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Rahul Aggarwal
- Target Recruit Count
- 25
- Registration Number
- NCT01594918
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸UCSF Comprehensive Cancer Center, San Francisco, California, United States
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 630
- Registration Number
- NCT01578655
- Locations
- 🇺🇸
Georgia Cancer Specialists, P.C., Marietta, Georgia, United States
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇿Krajská nemocnice Liberec a.s., Liberec, Czech Republic
A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-02-29
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Jeffrey Yachnin M.D., PhD.
- Target Recruit Count
- 100
- Registration Number
- NCT01541007
- Locations
- 🇸🇪
Deapartment of Oncology Karolinska University Hospital, Stockholm, Sweden
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2014-11-05
- Target Recruit Count
- 2
- Registration Number
- NCT01531205
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2017-06-14
- Target Recruit Count
- 101
- Registration Number
- NCT01528163
- Locations
- 🇧🇪
Grand Hôpital de Charleroi, Charleroi, Hainaut, Belgium
🇱🇺Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg
🇧🇪Hôpital de Jolimont, Haine-Saint-Paul, Hainaut, Belgium
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-01-09
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 170
- Registration Number
- NCT01505868
- Locations
- 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 179
- Registration Number
- NCT01500720
- Locations
- 🇷🇴
Investigational Site Number 642001, Craiova, Romania
🇬🇷Investigational Site Number 300005, Athens, Greece
🇺🇸Investigational Site Number 840006, Lebanon, New Hampshire, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.